Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease

British Journal of Haematology

Volumn 161, Issue 5, 2013, Pages 748-751

  Egan, Jan B ^a   Kortuem, K Martin ^a   Kurdoglu, Ahmet ^b   Izatt, Tyler ^b   Aldrich, Jessica ^b   Reiman, Rebecca ^b   Phillips, Lori ^b   Baker, Angela ^b   Shi, Chang Xin ^a   Schmidt, Jessica ^a   Liang, Winnie S ^b   Craig, David W ^b   Carpten, John D ^b   Stewart, A Keith ^a  

^a MAYO CLINIC   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

CRBN; Drug resistance; Myeloma; NR3C1; PSMG2

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN KAPPA CHAIN; SYNDECAN 1;

ADULT; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CASE REPORT; CEREBLON GENE; CHROMOSOME DELETION; CHROMOSOME INSERTION; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DOSAGE; GLUCOCORTICOID RECEPTOR GENE; HUMAN; HUMAN TISSUE; LETTER; MONOSOMY; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; NECK TUMOR; PILOT STUDY; POINT MUTATION; PRIORITY JOURNAL; PROTEASOME SUBUNIT G2 GENE; RNA SEQUENCE; SEQUENCE ANALYSIS; TUMOR GENE;

ADULT; CHAPERONINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENOME, HUMAN; HUMANS; MULTIPLE MYELOMA; MUTATION; NEOPLASM PROTEINS; PEPTIDE HYDROLASES; RECEPTORS, GLUCOCORTICOID;

EID: 84877796962     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12291     Document Type: Letter

References (10)

1. Bartholomeusz, C. & Gonzalez-Angulo, A.M. (2012) Targeting the PI3K signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16, 121-130.
2. Bray, P.J. & Cotton, R.G. (2003) Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Human Mutation, 21, 557-568.
3. Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., Getz, G. & Golub, T.R. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature, 471, 467-472.
4. Heuck, C.J., Szymonifka, J., Hansen, E., Shaughnessy, Jr, J.D., Usmani, S.Z., van Rhee, F., Anaissie, E., Nair, B., Waheed, S., Alsayed, Y., Petty, N., Bailey, C., Epstein, J., Hoering, A., Crowley, J. & Barlogie, B. (2012) Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. Clinical Cancer Research, 18, 5499-5506.
5. Hirano, Y., Hendil, K.B., Yashiroda, H., Iemura, S., Nagane, R., Hioki, Y., Natsume, T., Tanaka, K. & Murata, S. (2005) A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. Nature, 437, 1381-1385.
6. Janku, F., Wheler, J.J., Naing, A., Falchook, G.S., Hong, D.S., Stepanek, V., Fu, S., Piha-Paul, S.A., Lee, J.J., Luthra, R., Tsimberidou, A.M. & Kurzrock, R. (2012) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Research, 73, 276-284.
7. Keats, J.J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.J., Van Wier, S., Tiedemann, R., Shi, C.X., Sebag, M., Braggio, E., Henry, T., Zhu, Y.X., Fogle, H., Price-Troska, T., Ahmann, G., Mancini, C., Brents, L.A., Kumar, S., Greipp, P., Dispenzieri, A., Bryant, B., Mulligan, G., Bruhn, L., Barrett, M., Valdez, R., Trent, J., Stewart, A.K., Carpten, J. & Bergsagel, P.L. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell, 12, 131-144.
8. Moalli, P.A., Pillay, S., Weiner, D., Leikin, R. & Rosen, S.T. (1992) A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood, 79, 213-222.
9. Walker, B.A., Wardell, C.P., Melchor, L., Hulkki, S., Potter, N.E., Johnson, D.C., Fenwick, K., Kozarewa, I., Gonzalez, D., Lord, C.J., Ashworth, A., Davies, F.E. & Morgan, G.J. (2012) Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood, 120, 1077-1086.
10. Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.